Show simple item record

dc.creatorTopić-Vučenović, Valentina
dc.creatorRajkovača, Zvezdana
dc.creatorJelić, Dijana
dc.creatorStanimirović, Dragi
dc.creatorVuleta, Goran
dc.creatorMiljković, Branislava
dc.creatorVučićević, Katarina
dc.date.accessioned2019-09-02T12:07:34Z
dc.date.available2019-09-02T12:07:34Z
dc.date.issued2018
dc.identifier.issn0031-6970
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/3207
dc.description.abstractRadioiodine (I-131) therapy is the common treatment option for benign thyroid diseases. The objective of this study was to characterize I-131 biokinetics in patients with benign thyroid disease and to investigate and quantify the influence of patients' demographic and clinical characteristics on intra-thyroidal I-131 kinetics by developing a population model. Population pharmacokinetic analysis was performed using a nonlinear mixed effects approach. Data sets of 345 adult patients with benign thyroid disease, retrospectively collected from patients' medical records, were evaluated in the analysis. The two-compartment model of I-131 biokinetics representing the blood compartment and thyroid gland was used as the structural model. Results of the study indicate that the rate constant of the uptake of I-131 into the thyroid (k (tu)) is significantly influenced by clinical diagnosis, age, functional thyroid volume, free thyroxine in plasma (fT(4)), use of anti-thyroid drugs, and time of discontinuation of therapy before administration of the radioiodine (THDT), while the effective half-life of I-131 is affected by the age of the patients. Inclusion of the covariates in the base model resulted in a decrease of the between subject variability for k (tu) from 91 (3.9) to 53.9 (4.5)%. This is the first population model that accounts for the influence of fT(4) and THDT on radioiodine kinetics. The model could be used for further investigations into the correlation between thyroidal exposure to I-131 and the outcome of radioiodine therapy of benign thyroid disease as well as the development of dosing recommendations.en
dc.publisherSpringer Heidelberg, Heidelberg
dc.rightsrestrictedAccess
dc.sourceEuropean Journal of Clinical Pharmacology
dc.subjectRadioiodine uptakeen
dc.subjectVariabilityen
dc.subjectPopulation modelen
dc.subjectBenign thyroid disordersen
dc.titleInvestigation of factors influencing radioiodine (I-131) biokinetics in patients with benign thyroid disease using nonlinear mixed effects approachen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractСтанимировић, Драги; Вучићевић, Катарина; Јелић, Дијана; Миљковић, Бранислава; Вулета, Горан; Рајковача, Звездана; Топић-Вученовић, Валентина;
dc.citation.volume74
dc.citation.issue8
dc.citation.spage1037
dc.citation.epage1045
dc.citation.other74(8): 1037-1045
dc.citation.rankM22
dc.identifier.wos000438263100007
dc.identifier.doi10.1007/s00228-018-2459-8
dc.identifier.pmid29754217
dc.identifier.scopus2-s2.0-85046725962
dc.identifier.rcubconv_4152
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record